

amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of General Medical Sciences Special Emphasis Panel (SEP) meeting:

*Committee Name:* Minority Access to Research Careers (MARC) and Minority Biomedical Research Support (MBRS) Special Emphasis Panel.

*Date:* November 20, 1996.

*Time:* 12:30 p.m.—adjournment.

*Place:* National Institutes of Health (Telephone Conference), 45 Center Drive, Room 1AS-13F, Bethesda, MD 20892-6200.

*Contact Person:* Helen R. Sunshine, Ph.D., Chief, Office of Scientific Review, NIGMS, 45 Center Drive, Room 1AS-13F, Bethesda, MD 20892-6200, 301-594-2881.

*Purpose:* To evaluate and review grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 193.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS], National Institute of General Medical Sciences, National Institutes of Health)

Dated: October 30, 1996.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*  
[FR Doc. 96-28631 Filed 11-6-96; 8:45 am]

BILLING CODE 4140-01-M

**Prospective Grant of Exclusive License: Therapeutic Uses of Microtubule Stabilizing Agents Including Taxol (Paclitaxel) for Fibroproliferative Vascular Diseases Including Atherosclerosis and Restenosis and Excluding Cancer**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the

inventions embodied in the patents and patent applications referred to below to Angiotech Pharmaceuticals Inc. of Vancouver, British Columbia, Canada. The patent rights in these inventions have been assigned to the government of the United States of America. The patents and patent applications to be licensed are: "Methods of Treating Atherosclerosis or Restenosis Using Microtubule Stabilizing Agent," U.S. Patent Application Serial No. 08/099,067 filed July 29, 1993; and all continuation applications, divisional applications, continuation-in-part applications, and foreign counterpart applications related to U.S. Patent Application Serial No. 08/099,067.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within ninety (90) days with the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

**SUPPLEMENTARY INFORMATION:**

Atherosclerosis is the cause of the vast majority of cases of chronic peripheral arterial occlusive disease. The arteries most frequently involved, in order of occurrence, include femoropopliteal, aortoiliac, carotid and vertebral, splanchnic and renal, and brachycephalic. Fibromuscular dysplasia, inflammatory arteritides, and congenital arterial malformations are much rarer causes of arterial insufficiency. The process of repair after angioplasty continues over several months, involving re-endothelialization, proliferation of vascular smooth muscle cells, and remodelling of the extracellular matrix proteins. Restenosis, the natural regrowth of muscle cells, has been noted as the single greatest complication (30-50%) of interventional intravascular procedures which number approximately 500,000 procedure annually, and at \$10,000 per procedure is costing the health care system approximately \$5 billion annually. While both interventional and invasive treatments continue to improve, restenosis causes a first-time failure rate of up to 50% or more. Reduction in the restenosis rate for cardiovascular disease procedures is cited as the most critical factor in future improvements. If the rate could be reduced to 25%, it would represent a savings to the health care system of around \$1 billion annually.

Preventing or reducing fibroproliferative vascular disease in a patient may be achieved by treating the patient with a pharmaceutical preparation comprising a therapeutically effective amount of a microtubule stabilizing chemotherapeutic agent such as taxol (paclitaxel). In particular, treatment with a low dose of a microtubule stabilizing agent such as taxol or a water-soluble taxol derivative may present or reduce atherosclerosis or restenosis after arterial injury. The low dose used prevents artery blockage while minimizing any negative side effects associated with the drug. Unlike classical anti-microtubule agents like colchicine and the vinca alkaloids which induce depolymerization of microtubules, taxol induces tubulin polymerization and forms extremely stable and nonfunctional microtubules.

**ADDRESS:** Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to: J. Peter Kim, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: (301) 496-7056, ext. 264; Facsimile: (301) 402-0220. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before February 5, 1997 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 29, 1996.

Barbara M. McGarey,

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 96-28633 Filed 11-6-96; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF THE INTERIOR**

**Fish and Wildlife Service**

**Notice of Receipt of Applications for Permit**

The following applicants have applied for a permit to conduct certain

activities with endangered species. This notice is provided pursuant to Section 10(c) of the Endangered Species Act of 1973, *as amended* (16 U.S.C. 1531, *et seq.*):

PRT-821701

Applicant: Moscow Circus, New York, NY.

The applicant requests a permit to import and re-export leopards (*Panthera pardus*) and progeny of the animals currently held by the applicant and any animals acquired in the United States by the applicant to/from worldwide locations to enhance the survival of the species through conservation education. This notification covers activities conducted by the applicant over a three year period.

PRT-821553

Applicant: Saint Louis Zoological Park, St. Louis, MO.

The applicant requests a permit to import a total of three tissue samples and 15 blood samples collected from three clouded leopards (*Neofelis nebulosa*) held in captivity at the Toronto Zoo, Toronto, Canada, to enhance the survival of the species through scientific research.

PRT-821192

Applicant: Sacramento Zoo, Sacramento, CA.

The applicant requests a permit to import one, captive born, female snow leopard (*Panthera uncia*) from the Valley Zoo, Alberta, Canada for enhancement of the survival of the species through captive propagation and education.

Written data or comments should be submitted to the Director, U.S. Fish and Wildlife Service, Office of Management Authority, 4401 North Fairfax Drive, Room 430, Arlington, Virginia 22203 and must be received by the Director within 30 days of the date of this publication.

The public is invited to comment on the following application(s) for permits to conduct certain activities with marine mammals. The application(s) was/were submitted to satisfy requirements of the Marine Mammal Protection Act of 1972, *as amended* (16 U.S.C. 1361 *et seq.*) and the regulations governing marine mammals (50 CFR 18).

*Applicant:* Chicago Zool. Park, Brookfield Zoo, Brookfield, PRT-821744.

*Type of Permit:* Import for public display.

*Name and Number of Animals:* Pacific walrus (*Odobenus rosmarus*), 3.

*Summary of Activity to be Authorized:* The applicant has requested a permit to import from Sweden for the purpose of public display three juvenile

walrus initially collected from the wild in the area of the Chukotskiy Peninsula, Russia.

*Source of Marine Mammals for Research/Public Display:* Sweden.

*Period of Activity:* Up to five years from issuance of a permit, if issued.

Concurrent with the publication of this notice in the Federal Register, the Office of Management Authority is forwarding copies of this application to the Marine Mammal Commission and the Committee of Scientific Advisors for their review.

Written data or comments, requests for copies of the complete application, or requests for a public hearing on this application should be sent to the U.S. Fish and Wildlife Service, Office of Management Authority, 4401 N. Fairfax Drive, Room 430, Arlington, Virginia 22203, telephone 703/358-2104 or fax 703/358-2281 and must be received within 30 days of the date of publication of this notice. Anyone requesting a hearing should give specific reasons why a hearing would be appropriate. The holding of such hearing is at the discretion of the Director.

Documents and other information submitted with these applications are available for review, subject to the requirements of the Privacy Act and Freedom of Information Act, by any party who submits a written request for a copy of such documents within 30 days of the date of publication of this notice at the above address.

Dated: November 1, 1996.

Maryellen Amtower,

*Acting Chief, Branch of Permits, Office of Management Authority.*

[FR Doc. 96-28590 Filed 11-6-96; 8:45 am]

BILLING CODE 4310-55-P

## Bureau of Land Management

[MT-070-96-00]

### Resource Advisory Council Meeting, Butte, MT

**AGENCY:** Butte District Office, Bureau of Land Management, D.O.I.

**ACTION:** Notice of Butte District Resource Advisory Council Meeting, Butte, Montana.

**SUMMARY:** The Council will convene at 9 a.m. Wednesday, December 4, 1996. Issues that will be discussed include the draft Standards and Guidelines Environmental Impact Statement/Resource Advisory Council (RAC) participation at the open houses and prioritizing future RAC issues.

The meeting will be held at the District Office Conference Room, 106 North Parkmont, Butte, Montana.

The meeting is open to the public and written comments may be given to the Council. Oral comments may be presented to the Council at 3 p.m. The time allotted for oral comment may be limited, depending on the number of persons wishing to be heard. Individuals who plan to attend and need further information about the meeting, or need special assistance, such as sign language or other reasonable accommodations, should contact the Butte District, 106 North Parkmont (P.O. Box 3388), Butte, Montana 59702-3388; telephone 406-494-5059.

**FOR FURTHER INFORMATION CONTACT:** Jim Owings at the above address or telephone number.

Dated: October 28, 1996.

Orval L. Hadley,

*Acting District Manager.*

[FR Doc. 96-28620 Filed 11-6-96; 8:45 am]

BILLING CODE 4310-DN-M

[CA-060-07-1990-00]

### Meeting of the California Desert District Advisory Council

**SUMMARY:** Notice is hereby given, in accordance with Public Laws 92-463 and 94-579, that the California Desert District Advisory Council to the Bureau of Land Management, U.S. Department of the Interior, will meet in formal session on Thursday, December 5 from 8:00 a.m. to 5:00 p.m. and Friday, December 6, 1996, from 8:00 a.m. to 4:00 p.m. The Friday session will be held in the conference room in the Vacation Inn, located at 2000 Cottonwood Circle, El Centro, California.

Council members will participate in a field tour on Thursday morning. The tour will assemble at the Vacation Inn parking lot at 7:15 a.m., and depart at 7:30 a.m. The public is welcome to participate in the field tour, but should dress appropriately and plan on providing their own transportation, food, and beverage. Anyone interested in participating in the field tour should contact BLM at (909) 697-5215 for more information.

The Friday meeting will begin at 8 a.m. in the upstairs conference room at the Vacation Inn. All Desert District Advisory Council meetings are open to the public. Time for public comment may be made available by the Council Chairman during the presentation of various agenda items, and is scheduled at the end of the meeting for topics not on the agenda.

Written comments may be filed in advance of the meeting for the